Daihan Pharm 2026 Q1 Operating Profit Down, Dividend Up

2026 Q1 revenue KRW 52.7B (+5.7% YoY), operating profit KRW 7.86B (-14.6% YoY), net profit KRW 6.98B (-8.7% YoY)
2025 year-end cash dividend KRW 1,000/share (total KRW 5.88B), target payout ratio over 15%
Debt ratio 1.52%, net debt KRW 4.59B, cash equivalents KRW 47.1B – very sound financials
Holds 120,000 treasury shares (2.0%), no further buyback or cancellation plans
IV solutions account for 55.6% of sales; R&D expense KRW 383M (0.73% of revenue)
No material lawsuits or contingencies; FX exposure KRW 8.44B (USD 8.0B) poses currency risk